Our Journey & Honor
Our Experts
Management Team
Our Company
Our Vision
Asieris Pharmaceuticals

      Asieris Pharmaceuticals was founded in March 2010 in China Medical City (the first national medical high-tech industrial park in China), in the City of Taizhou, Jiangsu Province. Recently the company has expanded its operations to Shanghai Zhangjiang High-Tech Park for clinical research, cancer biology research and business development, and to the United States for international clinical development and business development.   亚虹图标20180425

      Asieris Pharmaceuticals is dedicated to becoming a China-based biotech company with significant global impacts in our focused therapeutic areas in oncology and multidrug-resistant infections. One of our R&D strategies is to leverage the extensive knowledge of "old drugs" for creating breakthrough innovations.

        Our founding and senior management team comprises of experts each with 20+ years of experiences in multi-national pharmaceutical companies. We have also attracted many management members from leading pharmaceutical companies in China. They have a wealth of experiences in drug research and development in China as well great ambitions to catch up the global advancements.

        Our leading candidate, APL-1202, is potentially the first oral drug for treating non-muscle-invasive bladder cancer (NMIBC). Supported by China's "National 12th 5-Year important Innovations" grant, APL-1202's preliminary results from a phase II trial was presented in 2016 European Association of Urology annual congress in Munich. Now APL-1202 is in a pivotal trial in China, and its 2nd-generation APL-1301 is entering global clinical development stage. Additionally, Asieris has multiple first-in-class anti-tumor and anti-infectious drugs in preclinical developments.